The monoclonal antibodies target molecular cell surface receptors of tumor cells enabling blockade of proliferative pathways (e.g., HER2, PD-L1) or tumor-infiltrating immune cell subsets in the tumor microenvironment hampering the activation of immune cells by tumor cells and abolishing the tumor. Here, ERBB2 is linked to neoplasm.